Description
CNX-774 inhibits Bruton’s tyrosine kinase (BTK) and displays potential anticancer and immunosuppressive activities.
CNX-774
Product ID C5592
Cas No. 1202759-32-7
Purity ≥97%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 1202759-32-7 |
|---|---|
| Purity | ≥97% |
| Formula | C26H22FN7O3 |
| Formula Wt. | 499.50 |
| IUPAC Name | 4-[4-[[5-fluoro-4-[3-(prop-2-enoylamino)anilino]pyrimidin-2-yl]amino]phenoxy]-N-methylpyridine-2-carboxamide |
| Synonym | CNX774 |
| Solubility | DMSO 100 mg/mL (200.2 mM) Ethanol 2 mg/mL (4.0 mM) Water Insoluble |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013 Aug 19;6:59. PMID: 23958373.